炎症性肠病病程预测的血清学和实验室标志物。
Serologic and laboratory markers in prediction of the disease course in inflammatory bowel disease.
机构信息
Pediatric IBD Center, Department of Pediatrics, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
出版信息
World J Gastroenterol. 2010 Jun 7;16(21):2604-8. doi: 10.3748/wjg.v16.i21.2604.
Abstract
The search for biologic markers that can assess the natural history and perhaps predict the course of individual's disease including response to treatments over time has become an important focus of inflammatory bowel disease research. The knowledge of an individual's prognosis can help physicians and patients make important management decisions and aid communication on risk and benefits of disease and treatment.
摘要
寻找能够评估疾病自然史并预测个体疾病进程（包括随时间推移对治疗的反应）的生物标志物，已成为炎症性肠病研究的一个重要重点。了解个体的预后有助于医生和患者做出重要的管理决策，并有助于就疾病和治疗的风险和益处进行沟通。
相似文献
1
Serologic and laboratory markers in prediction of the disease course in inflammatory bowel disease.
World J Gastroenterol. 2010 Jun 7;16(21):2604-8. doi: 10.3748/wjg.v16.i21.2604.
2
Can serologic markers help determine prognosis and guide therapy?
Dig Dis. 2010;28(3):424-8. doi: 10.1159/000320397. Epub 2010 Sep 30.
3
Advances in Use of Endoscopy, Radiology, and Biomarkers to Monitor Inflammatory Bowel Diseases.
Gastroenterology. 2017 Feb;152(2):362-373.e3. doi: 10.1053/j.gastro.2016.10.005. Epub 2016 Oct 15.
4
Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
Am J Gastroenterol. 2008 Jan;103(1):162-9. doi: 10.1111/j.1572-0241.2007.01556.x. Epub 2007 Oct 4.
5
Surrogate Markers of Intestinal Inflammation in Paediatric Patients with Inflammatory Bowel Disease.
Folia Med (Plovdiv). 2020 Jun 30;62(2):271-275. doi: 10.3897/folmed.62.e47830.
6
Fecal Calprotectin Is Not Affected by Pregnancy: Clinical Implications for the Management of Pregnant Patients with Inflammatory Bowel Disease.
Inflamm Bowel Dis. 2017 Jul;23(7):1240-1246. doi: 10.1097/MIB.0000000000001136.
7
High Percentage of IBD Patients with Indefinite Fecal Calprotectin Levels: Additional Value of a Combination Score.
Dig Dis Sci. 2017 Feb;62(2):465-472. doi: 10.1007/s10620-016-4397-6. Epub 2016 Dec 8.
8
Utility of faecal calprotectin analysis in adult inflammatory bowel disease.
World J Gastroenterol. 2012 Dec 14;18(46):6782-9. doi: 10.3748/wjg.v18.i46.6782.
9
What changes in inflammatory bowel disease management can be implemented today?
J Crohns Colitis. 2012 Feb;6 Suppl 2:S260-7. doi: 10.1016/S1873-9946(12)60506-6.
10
Biomarkers of Inflammation in Inflammatory Bowel Disease: How Long before Abandoning Single-Marker Approaches?
Dig Dis. 2021;39(3):190-203. doi: 10.1159/000511641. Epub 2020 Sep 17.
引用本文的文献
1
Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Disease Outcome and Response to Therapy.
J Crohns Colitis. 2021 Sep 25;15(9):1431-1442. doi: 10.1093/ecco-jcc/jjab050.
2
The Role of Early Biologic Therapy in Inflammatory Bowel Disease.
Inflamm Bowel Dis. 2019 Nov 14;25(12):1896-1905. doi: 10.1093/ibd/izz059.
3
New Trends in Inflammatory Bowel Disease.
GE Port J Gastroenterol. 2015 May 11;22(3):103-111. doi: 10.1016/j.jpge.2015.03.009. eCollection 2015 May-Jun.
4
Dysregulation of innate immunity in ulcerative colitis patients who fail anti-tumor necrosis factor therapy.
World J Gastroenterol. 2016 Nov 7;22(41):9104-9116. doi: 10.3748/wjg.v22.i41.9104.
5
The Effect of Serum 25-Hydroxyvitamin D Concentrations on Elevated Serum C-Reactive Protein Concentrations in Normal Weight, Overweight and Obese Participants of a Preventive Health Program.
Nutrients. 2016 Nov 4;8(11):696. doi: 10.3390/nu8110696.
6
Treatment of inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 2(nd) Asian Organization of Crohn's and Colitis (AOCC) meeting in Seoul.
Intest Res. 2016 Jul;14(3):231-9. doi: 10.5217/ir.2016.14.3.231. Epub 2016 Jun 27.
7
Results of the first survey for the current status of inflammatory bowel disease management in Asian countries.
Intest Res. 2016 Jul;14(3):199-201. doi: 10.5217/ir.2016.14.3.199. Epub 2016 Jun 27.
8
In the pipeline.
Gastroenterol Hepatol (N Y). 2014 Jun;10(6):396.
9
Risk assessment in Crohn's disease.
Gastroenterol Hepatol (N Y). 2014 Jun;10(6):392-4.
10
Characteristics of inflammatory bowel disease serology in patients with indeterminate colitis.
J Clin Gastroenterol. 2014 Apr;48(4):351-5. doi: 10.1097/MCG.0000000000000083.
本文引用的文献
1
Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse.
Inflamm Bowel Dis. 2009 Aug;15(8):1190-8. doi: 10.1002/ibd.20933.
2
Can calprotectin predict relapse risk in inflammatory bowel disease?
Am J Gastroenterol. 2008 Aug;103(8):2007-14. doi: 10.1111/j.1572-0241.2008.01870.x.
3
Increased immune reactivity predicts aggressive complicating Crohn's disease in children.
Clin Gastroenterol Hepatol. 2008 Oct;6(10):1105-11. doi: 10.1016/j.cgh.2008.04.032. Epub 2008 Jul 10.
4
Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after ileal pouch-anal anastomosis.
Clin Gastroenterol Hepatol. 2008 May;6(5):561-8. doi: 10.1016/j.cgh.2008.01.002. Epub 2008 Apr 18.
5
Family history and serology predict Crohn's disease after ileal pouch-anal anastomosis for ulcerative colitis.
Dis Colon Rectum. 2008 Jan;51(1):100-8. doi: 10.1007/s10350-007-9158-3. Epub 2007 Dec 18.
6
New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort.
Am J Gastroenterol. 2008 Mar;103(3):665-81. doi: 10.1111/j.1572-0241.2007.01652.x. Epub 2007 Nov 28.
7
New serological markers in inflammatory bowel disease are associated with complicated disease behaviour.
Gut. 2007 Oct;56(10):1394-403. doi: 10.1136/gut.2006.108043. Epub 2007 Apr 24.
8
Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease.
Gastroenterology. 2006 Aug;131(2):366-78. doi: 10.1053/j.gastro.2006.04.030.
9
A simple biological score for predicting low risk of short-term relapse in Crohn's disease.
Inflamm Bowel Dis. 2006 Jul;12(7):551-7. doi: 10.1097/01.ibd.0000225334.60990.5b.
10
Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn's disease patients.
Am J Gastroenterol. 2006 Mar;101(3):645-52. doi: 10.1111/j.1572-0241.2006.00468.x. Epub 2006 Feb 8.
Zotero 插件